BioXcel Therapeutics
BTAI on Nasdaq. Market value $6m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
We don't have fund holdings for this stock yet.
Big holders and activists
3 investors own more than 5%.
- Integrated Core Strategies (US) LLCPassive investorat least 8.4%+3.2 pts(filed with 3 related holders)Since 31 December 2025
- Armistice Capital, LLCPassive investorat least 5.0%−2.1 pts(filed with 1 related holder)Since 30 June 2026
- Oaktree Capital Holdings, LLCPassive investorat least 2.7%−2.5 pts(filed with 3 related holders)Since 31 March 2025
- Qatar Investment AuthorityPassive investorSold down below 5%Since 31 December 2025
| Holder | Stake | Since | |
|---|---|---|---|
Integrated Core Strategies (US) LLC Passive investor | at least 8.4%+3.2 pts (filed with 3 related holders) | 31 December 2025 | |
Armistice Capital, LLC Passive investor | at least 5.0%−2.1 pts (filed with 1 related holder) | 30 June 2026 | |
Oaktree Capital Holdings, LLC Passive investor | at least 2.7%−2.5 pts (filed with 3 related holders) | 31 March 2025 | |
Qatar Investment Authority Passive investor | Sold down below 5% | 31 December 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 4 sold $43,174, $43,174 of it under preset trading plans.
- Yocca FrankChief Scientific OfficerSoldunder a preset trading plan
- Date
- 20 May 2026
- Shares
- 6,845
- Price
- $1.09
- Value
- $7,461
- Rodriguez JavierSee RemarksSoldunder a preset trading plan
- Date
- 20 May 2026
- Shares
- 6,560
- Price
- $1.08
- Value
- $7,085
- Steinhart Richard IChief Financial OfficerSoldunder a preset trading plan
- Date
- 20 May 2026
- Shares
- 6,845
- Price
- $1.09
- Value
- $7,461
- Mehta VimalCEO and President, DirectorSoldunder a preset trading plan
- Date
- 20 May 2026
- Shares
- 19,419
- Price
- $1.09
- Value
- $21,167
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 20 May 2026 | Yocca Frank Chief Scientific Officer | Sold under a preset trading plan | 6,845 | $1.09 | $7,461 |
| 20 May 2026 | Rodriguez Javier See Remarks | Sold under a preset trading plan | 6,560 | $1.08 | $7,085 |
| 20 May 2026 | Steinhart Richard I Chief Financial Officer | Sold under a preset trading plan | 6,845 | $1.09 | $7,461 |
| 20 May 2026 | Mehta Vimal CEO and President, Director | Sold under a preset trading plan | 19,419 | $1.09 | $21,167 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in BioXcel Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 27 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 11 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“The Company’s history of significant losses, its negative cash flows from operations, its current debt obligations, potential near-term increased covenant-driven amortization payments under its Credit Agreement (as defined in Note 9, Debt and Credit Facilities ), its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management’s assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report.”
From the 10-Q filed 13 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.